Clinical Trial

Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 8, 2023 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
Hydrogen sulfide is a signaling molecule that is important for vascular health. Because vascular factors such as hypertension and high cholesterol are risk factors for Alzheimer's disease and related dementias, we hypothesize that hydrogen sulfide plays an important role in brain health as well. We will compare blood levels of hydrogen sulfide across groups of people with and without dementia. We will also look at the relationship between hydrogen sulfide, cognitive dysfunction and measures of brain microvascular disease examine the contribution of hydrogen sulfide to cognitive decline. Our goal is to identify a biomarker of vascular dysfunction in dementia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-09-20.
Status change: Recruiting → Active, Not Recruiting 2023-03-07
Trial Details
NCT Number NCT05060848
Lead Sponsor Louisiana State University Health Sciences Center Shreveport
Conditions Alzheimer Disease, Dementia
Enrollment 100 participants
Start Date 2021-04-01
Primary Completion 2026-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2023-03-08